Clinical Trial Update: Once a Day (QD) - Twice a Day (BID) Clinical Trial: Didanosine, Lamivudine and Efavirenz Versus Zidovudine, Lamivudine and Efavirenz in the Starting Treatment of HIV [Phase 4]

View source ↗

Summary

Phase 4 trial comparing once-daily didanosine/lamivudine/efavirenz versus twice-daily zidovudine/lamivudine/efavirenz as initial HIV therapy has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• HIV Infection

Drugs mentioned

• Didanosine (didanosine)
• EFAVIRENZ (efavirenz)
• Lamivudine (lamivudine)
• Zidovudine (Zidovudine)

Snippet

Sponsor: Clinical Trial Agency of HIV Study Group | Conditions: HIV Infections | Phase 4 | Status: COMPLETED